Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
16,307
Total Claims
$2.1M
Drug Cost
458
Beneficiaries
$4,510
Cost/Patient
Risk Score Breakdown 43/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+448%
Opioid rate vs peers
12.3% vs 2.2% avg
+220%
Cost per patient vs peers
$4,510 vs $1,411 avg
+42%
Brand preference vs peers
15.1% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Opioid rate is 448% above Internal Medicine peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
12.3%
Opioid Rate
2,002
Opioid Claims
$137K
Opioid Cost
15.0%
Long-Acting Rate
Brand vs Generic
Brand: 2,443 claims · $1.6M
Generic: 13,699 claims · $461K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 179 | $215K |
| Dulaglutide | 114 | $113K |
| Apixaban | 172 | $108K |
| Etanercept | 14 | $107K |
| Octreotide Acetate,mi-Spheres | 14 | $100K |
| Linaclotide | 120 | $83K |
| Fluticasone/Umeclidin/Vilanter | 82 | $59K |
| Dapagliflozin Propanediol | 57 | $50K |
| Mirabegron | 98 | $49K |
| Cariprazine Hcl | 30 | $44K |
| Oxycodone Hcl | 52 | $42K |
| Rifaximin | 11 | $38K |
| Budesonide/Formoterol Fumarate | 68 | $37K |
| Sitagliptin Phosphate | 34 | $36K |
| Insulin Detemir | 46 | $36K |
Prescribing Profile
Patient Profile
71
Avg Age
56%
Female
1.87
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About